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Abstract
Background: Pulmonary arterial hypertension (PAH) is a rare vascular disorder characterized by a capillary wedge
pressure ≤ 15 mmHg and a mean pulmonary arterial pressure ≥ 25 mmHg at rest. PAH can be idiopathic, heritable
or associated with other conditions. The aim of this study was to analyze the Endoglin (ENG) gene and assess the
influence of the c.572G > A (p.G191D) mutation in patients with idiopathic or associated PAH. The correlation
between the pathogenic mutations and clinical and functional parameters was further analyzed.
Results: Sixteen different changes in the ENG gene were found in 44 out of 57 patients. After in silico analysis, we
classified eight mutations as pathogenic in 16 of patients. The c.572G>A (p.G191D) variation was observed in ten
patients, and the analysis for the splicing process using hybrid minigenes, with pSPL3 vector to assess splicing
alterations, do not generate a new transcript. Age at diagnosis (p = 0.049) and the 6-min walking test (p = 0.041)
exhibited statistically significant differences between carriers and non-carriers of pathogenic mutations. Patients
with pathogenic mutations exhibited disease symptoms 8 years before non-carriers. Five patients with pathogenic
mutations were carriers of another mutation in the BMPR2 or ACVRL1 genes.
Conclusions: We present a series of PAH patients with mutations in the ENG gene, some of them not previously
described, exhibiting clinical and hemodynamic alterations suggesting that the presence of these mutations may
be associated with the severity of the disease. Moreover, genetic analysis in patients with PAH may be of clinical
relevance and indicates the complexity of the genetic background.
Keywords: Pulmonary arterial hypertension, ENG gene, Mutational analysis, Functional study, Genotype-phenotype
correlation
Background
Pulmonary arterial hypertension (PAH; OMIM #178600;
ORPHA 422) is a severe disease affecting small pulmon-
ary arteries that results in progressive remodeling lead-
ing to elevated pulmonary vascular resistance and right
ventricular failure [1]. PAH can be idiopathic (IPAH),
heritable (HPAH) or associated with other conditions
(APAH) [2]. PAH is characterized by a capillary wedge
pressure ≤ 15 mmHg and mean pulmonary arterial pres-
sure ≥ 25 mmHg at rest [1, 2]. Symptoms of PAH are
mixed but include dyspnea, syncope and chest pain.
Eventually, the disease in these patients leads to right-
sided heart failure and death [1]. The main pathologic
changes associated with increased pulmonary vascular
resistance are thrombus development, thickened intima,
proliferation of smooth muscles cells, and growth of
plexiform lesions in pulmonary vessels [3]. The estimated
incidence is approximately 2–5 cases per million per year
[3], and the gender ratio is 1.7:1 female vs male [4, 5].
Without treatment, the disease progresses to right ven-
tricular failure and death within 3 years of diagnosis [6].
Heterozygous germline mutations in the bone morpho-
genetic protein type 2 receptor (BMPR2; MIM #600799)
have been identified in approximately 10 to 40 % of IPAH
patients without a reported familial history of the disease
and in over 80 % of patients with HPAH [4, 7–9]. PAH
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patients with BMPR2 mutations are reported to develop
more severe disease, are less likely to respond to treatment
and are diagnosed approximately 10 years earlier than
non-carriers [10]. In a few PAH patients, mutations in
other genes participating in the BMPR2 signaling pathway
have been reported, including Endoglin, also known as
CD105, (ENG; MIM #601284) [11]. ENG gene mutations
are less common than BMPR2 gene mutations in patients
with PAH. Accordingly, a more complicated genetic back-
ground has been proposed for PAH [7].
The ENG gene encodes a type I integral membrane
glycoprotein receptor that is a member of the Trans-
forming growth factor beta (TGF-β) signaling superfam-
ily. This receptor is expressed on proliferating vascular
endothelial cells and in other cell types associated with
cardiovascular system and controls diverse cellular pro-
cesses, including cell differentiation, proliferation, angio-
genesis, inflammation, and wound healings and has been
linked to psoriatic skin, inflamed synovial arthritis, vas-
cular injury, tumor vessels and apoptosis in embryonic
and mature tissues [12–15]. The human ENG gene is lo-
cated on chromosome 9q33-34 [7, 13, 14], and the encoded
protein exhibits an extracellular domain, hydrophobic
transmembrane domain and a cytosolic domain. The extra-
cellular domain contains 561 amino acids and is the largest
of the domains [13]. This gene is implicated in hereditary
hemorrhagic telangiectasia (HHT) type 1, an autosomal
dominant syndrome characterized by vascular dysplasia.
Mutations found in the ENG gene are an important factor
for the development of HHT and may contribute to
PAH in some HHT patients due to the gene’s function
as a TGF-β receptor [7, 13–16]. Mutations in this gene
are frequently identified in HHT but are uncommon in
PAH patients [4, 15, 17].
The potential role of ENG gene in patients with PAH
remains unknown. To analyze its impact in patients with
IPAH and APAH, we analyzed the coding region and
intronic junctions of this gene and try to associate
hemodynamic and clinical characteristics between car-
riers and non-carriers of ENG mutations. To evaluate
the effect of ENG mutations on clinical outcomes of
PAH, the phenotypical characteristic of carriers of mis-
sense mutations and carriers of mutations that alter the
splicing in this gene were compared.
Methods
Patients and samples
As described previously [8], patients with idiopathic or
associated PAH (group 1 of the classification of Nice)
[18] treated in our clinic were included in this study. All
patients are included in the CHUVI DNA Biobank (Bio-
banco del Complejo Hospitalario Universitario de Vigo).
Patients signed an informed consent and the Autonomic
Ethics Committee approved the study (Comité Autonómico
de Ética da Investigación de Galicia-CAEI de Galicia).
In all cases, cardiac catheterization was performed using
the latest consensus diagnostic criteria of the ERS-ESC
(European Respiratory Society-European Society of Cardi-
ology) [19]. PAH was considered idiopathic after the ex-
clusion of any of the possible causes associated with the
disease. Clinical histories included use of drugs, especially
appetite suppressants, and screening for connective tissue
diseases and hepatic disease. The study included serology
for Human immunodeficiency virus (HIV), autoimmunity,
thoracic tomography computerized scan (TC scan) and
echocardiography. Patients with PAH that could be related
to chronic lung disease were excluded. Fifty-five healthy
individuals were used as controls.
Mutational analysis
Venous blood was collected from patients and healthy
volunteers to extract genomic DNA using the FlexiGene
DNA Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s protocol.
Amplification of the ENG gene was performed with
50 ng of genomic DNA from each patient and control.
We amplified the exon regions and intronic junctions
and did not analyzed changes in other regions for this
study. The primers use to amplified this region by PCR
(Polymerase chain reaction) were described by Gallione
et al [20], with minor modifications (Table 1). The PCR
mix was GoTaq® Green Master Mix (Promega Corpor-
ation, Madison, Wisconsin, USA), which contained Taq
DNA polymerase, dNTPs, MgCl2 and reaction buffer. A
second independent PCR and sequencing reaction in
both the forward and reverse strands was performed to
check for the detected mutations. PCR was performed
in an MJ MiniTM Gradient Thermal Cycler (Bio-Rad,
Hercules, California, USA). Electrophoresis on a 2 %
agarose gel containing ethidium bromide was per-
formed to confirmed PCR products in a Sub-Cell GT
(Bio-Rad, Hercules, California, USA). HyperLadder
IV-V (New England Biolabs, Ipswich, Massachusetts,
USA) was used as the molecular weight marker. PCR
fragments were purified using the ExoSAP-IT kit (USB
Corporation, Cleveland, Ohio, USA) and sequenced
with the BigDye Terminator version 3.1 Cycle Sequencing
Kit (Applied Biosystems, Carlsbad, California, USA). The
sequencing reactions were precipitated and analyzed on
an ABI PRISM 3100 genetic analyzer (Applied Biosystems,
Carlsbad, California, USA).
Sequence data were aligned to the reference Ensembl
cDNA sequence ENSG00000106991 for the ENG gene
and examined for sequence variations. To align and
compare sequences in different organisms we use the
Basic Local Alignment Search Tool (BLAST) software.
Polyphen-2 (available at http://genetics.bwh.harvard.edu/
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pph/) characterize an amino acid substitution as “be-
nign”, “possibly damaging” or “probably damaging” [21],
Pmut (available at http://mmb2.pcb.ub.es:8080/PMut/)
provides a binary prediction of “neutral” or “pathologic”
[22], Sort Intolerant from Tolerant (SIFT) (available at
http://sift.jcvi.org) predict whether a change is “toler-
ated” or “damaging” [23] and MutationTaster2 software
(available at http://www.mutationtaster.org/) characterize
an amino acid substitution as “polymorphism” or “disease
causing” [24] computer algorithms were used to predict
whether missense variants were pathological. A brief ex-
planation for these software programs is provided in Pou-
sada et al [8]. The mutations were classified as pathogenic
if the score were equal or greater than two.
NNSplice (available at http://fruitfly.org:9005/seq_tools/
splice.html), NetGene2 (available at http://www.cbs.dtu.dk/
services/NetGene2/), Splice View (available at http://zeu-
s2.itb.cnr.it/~webgene/wwwspliceview_ex.html) and HSF
Human (available at http://www.umd.be/HSF/) were used
to predict whether changes could affect, create or eliminate
donor/acceptor splice sites [8]. The mutations were
classified as pathogenic if the score were equal or greater
than two.
Minigene constructions and expression
For the c.572G>A (p.G191D) change, we amplified the
exon and 200 bp of intronic junctions from the control
DNA with High Fidelity Phusion polymerase (Finnzymes,
Espoo, Finland) to obtain the wild-type (WT). The ampli-
fication conditions were as follows: 98 °C for 30 s, 35 cycles
of 98 °C for 10 s, 60 °C for 30 s, 72 °C for 30 s and, finally,
72 °C for 7 min. The amplified fragments were digested
and cloned into the XhoI/NheI restriction sites (Nzytech,
Lisbon, Portugal) using T4 DNA ligase (New England
Biolabs, Ipswich, Massachusetts, USA) in the Exon
Trapping Expression Vector p.SPL3 (Invitrogen, San Diego,
California, USA). The c.572G>A (p.G191D) construct was
generated by site-directed mutagenesis. The primers used
for mutagenesis were designed using QuikChange Primer
Design (Agilent Technologies, Santa Clara, California,
USA). The forward and reverse primers were 5'-gccagga
catggaccgcacgctcga-3' and 5'-tcgagcgtgcggtccatgtcctggc-3',
respectively. All constructs were confirmed by direct
sequencing.
COS-7 cells (from kidney of Cercopithecus aethiops)
were transfected in duplicated by the minigene constructs.
Lipofectamine 2000 reagents (Invitrogen, San Diego, CA,
USA) were used according to the manufacturer’s instruc-
tions. RNA extraction was performed using the Nucleic
Acid and Protein Purification kit (NucleoSpin RNA II,
Macherey-Nagel, Düren, Germany). RNA was subjected
to reverse transcription using the GeneAmp Gold RNA
PCR Core Kit (Applied Biosystems, Carlsbad, California).
cDNA was amplified and PCR products were sequenced
in both senses.
Statistical analysis
A non-parametric test (U Mann-Whitney) was used for
comparisons between patients and controls and this study
is exploratory. The Chi-square test was used to compare
genotypes with clinical and hemodynamic variables and
variables were categorized according to the best cut off
point by ROC curve. Analyses were supported by the stat-
istical package SPSS v19 for Microsoft and we considered
Table 1 Primers used to amplify the ENG gene
EXON PRIMERS SIZE Tª
Forward 5’→ 3’ Reverse 5’→ 3’
1 ACTGGACACAGGATAAGGCCCAGC AATACTTGGGGCCTGGTCCGTG 180 bp 62 °C
2 CACCTTATTCTCACCTGGCCTCTT CTGCCTTGGAGCTTCCTCTGAG 249 bp 61 °C
3 GGGTGGCACAACCTATACAAAT CAGAGATGGACAGTAGGGACCT 269 bp 60 °C
4 CTACATGGGATAGAGAGGGCAC TTCCTCCTGAGCAGTATCATGAG 277 bp 55 °C
5 TGAGGGAAGGGACTGAGGTGC GTGGGGACTAGTGTCAGGGGC 238 bp 63 °C
6 GGCCTGTCCGCTTCAGTGTT GTTTTGTGTCCCGGGAGCTG 203 bp 58 °C
7 CCCCCTGTTCTGCCTCTCTC CTGATCCAAGGGAGGGGAAG 256 bp 63 °C
8 ACACATATCACACAGTGACCAGC CTAGGGGAGGAACCAGATGTC 253 bp 55 °C
9 CTCCTGATGGTGCCCCTCTCTTC TTGTCTTGTGTTCTGAGCCCCTG 296 bp 60 °C
10 CTGCAGGGGCTCAGAACACA GGCCAGGTGGGTTAGCACG 212 bp 61 °C
11 ATTGACCAAGTCTCCCTCCC GAAAGGCGGAGAGGAAGTTC 211 bp 61 °C
12 GGTGGGGTGAAGAGCAGCTG GACCTGGAAGCTCCCACTTGAA 359 bp 58 °C
13 GAGTAAACCTGGAAGCCGC GCCACTAGAACAAACCCGAG 154 bp 55 °C
14 A CCAGCACAACAGGGTAGGGGAT CTCAGAGGCTTCACTGGGCTCC 255 bp 61 °C
14 B AGGACCCTGACCTCCGCC CTCTCCTGCTGGGCGAGC 198 bp 63 °C
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differences statistically significant at values <0.05. Values
were expressed as the mean ± SD (standard deviation).
Results
Description of the cohort
This cohort has been described previously by our group
[8, 25] and included 57 unrelated PAH patients (29
idiopathic, 19 associated with connective tissue disease,
four related to HIV and five porto-pulmonary) (Fig. 1).
Samples from PAH patients who agreed to participate
in the study were collected between 2008 and 2014. At
the time of diagnosis, eight patients were functional
class (FC) I, 20 patients were FC II, 25 patients were FC
III and four were FC IV. The clinical features of the pa-
tients are presented in Table 2.
In the present study, 55 controls from the general
population without a familial history of PAH were included
to determine the frequency of the mutations detected in
the ENG gene. Samples were kindly provided by the Com-
plexo Hospitalario Universitario de Vigo (Vigo, Spain).
Mutational study of the ENG gene
We found 15 variants of the ENG gene in 44 out of 57
patients. We detected eight different variations first de-
scribed here and seven changes that have been described
elsewhere. The vast majority of these changes were de-
tected in amplicon 7 and 11 (Fig. 2), but we detected the
exons 6 and 12 as hotspots for pathogenic mutations. The
novel variations did not appear in 55 analyzed controls
(110 chromosomes). After an exhaustive in silico analysis,
we could identify 8 variations as pathogenic mutations.
Missense variations were analyzed with different software
programs (PolyPhen, Pmut, Sift and Mutation Taster) to
predict their pathogenicity and the impact on the disease.
We classified the mutation as potentially pathogenic if
two or more programs classified it as pathogenic (Table 3).
These analyses classified five missense mutations as patho-
genic mutations; however, c.572G>A (p.G191D) has been
classified as polymorphism by other studies [26–28].
Figure 3 presents the amino acid conservation involved
in these missense changes. We observed that the wild-
type residues in the p.(S432C) and p.(R554C) mutations
are not perfectly conserved between Homo sapiens (human)
and ten other species, but are conserved amongst some of
the species analyzed.
For the six intronic changes detected, only a duplication
(c.991 + 21_991 + 26dupCCTCCC) had been described
previously as a polymorphism. This duplication was de-
tected in 35 % of patients included in this study but
also in 8 % of controls.
We used other algorithms (NNSplice, NetGene2, Splice
View and HSF Human) to predict whether these mis-
sense, synonymous and intronic changes could affect
donor/acceptor splice sites. We classified the mutation
as potentially pathogenic if two or more programs classi-
fied it as pathogenic (Table 4).
These pathogenic mutations were detected in 16 pa-
tients, four mutations were missense (except c.572G > A
(p.G191D), as has been classified as polymorphism by
other authors), one synonymous and three were located in
the intronic region. Of these patients, seven were classified
as IPAH and in nine as APAH.
Study of the c.572G>A (p.G191D) change
This change c.572G>A (p.G191D) was found in ten pa-
tients included in this study and was more frequent in
IPAH than in patients with APAH. This change was not
detected in 110 control alleles (p = 0.001). In patients,
Fig. 1 Nature of the patient cohort. This figure describes the patients involved in this analysis separated by PAH type, the proportion of mutation
carriers in the study, the female to male proportion and the mean age at diagnosis. PAH: Pulmonary Arterial Hypertension; IPAH: Idiopathic
Pulmonary Arterial Hypertension; Associated Pulmonary Arterial Hypertension; CTD: connective tissue disease; HIV: Human Immunodeficiency
virus; P-P: Porto-pulmonary hypertension
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the G allele frequency was 0.909 (90 %). Allele A was
not detected in controls. This change was not in Hardy-
Weinberg Equilibrium (H-WE) in patients (p = 0.617), in
contrast to the controls (p < 0.001). BLAST software indi-
cated that the G amino acid (glycine) is an evolutionarily
conserved residue (Fig. 4). We checked for alterations in
the splicing process using hybrid minigenes for this gene
in comparison to the wild type sequence. The mutant con-
struct did not generate a new transcript (Fig. 5). All exper-
iments were performed in duplicate.
Association with clinical features and hemodynamic
parameters
None of the clinical features or hemodynamic parameters
exhibited statistically significant differences, except for age
at diagnosis (p = 0.040) and the 6-min walking test
(p = 0.040). Patients with pathogenic mutations in ENG
gene exhibited disease symptoms 8 years earlier and were
diagnosed earlier than patients with a negative mutational
screening for ENG, BMPR2, ACVRL1 (Activin A Receptor
Type II-Like 1) and KCNA5 (Potassium voltage-gated chan-
nel, shaker-related subfamily, member 5) genes (Table 2).
However, five patients with ENG pathogenic mutations
were also carriers for another mutation in the BMPR2
or ACVRL1 genes (Fig. 6) as described by Pousada et al
[8]. When removing these patients for statistical ana-
lysis, only age at diagnosis was significantly different
(mean 9 years early, p = 0.040).
The c.572G>A (p.G191D) change was associated with
an early age at diagnosis (mean 10 years earlier, p = 0.035)




Total patients Carriers of pathogenic mutationsa Carriers of p.G191N mutationb
Clinical data p-value Clinical data p-value
Number 57 16 ———————— 10 ————————
Gender 21 M/36 F 6 M/10 F n.s 2 M/8 F n.s
Age at diagnosis (years) 49 ± 15 41 ± 16 0.040 39 ± 18 0.035
mPaP (mmHg) 49 ± 14 48 ± 11 n.s 45 ± 12 n.s
sPaP (mmHg) 70 ± 19 75 ± 16 n.s 67 ± 18 n.s
PVR (mmHg.l−1.m−1) 8.2 ± 3.5 8.6 ± 3.2 n.s 8.3 ± 0.9 n.s
CI (l.m−1.m−2) 2.6 ± 0.6 2.5 ± 0.7 n.s 2.1 ± 0.5 0.049
6MWT (m) 445 ± 139 323 ± 162 0.040 457 ± 172 n.s
PAH types 29 IPAH/28 APAH 7 IPAH/9 APAH n.s 8 IPAH/2 APAH 0.040
Values are expressed as the mean ± standard deviation; F female, M male, mPaP mean pulmonary artery pressure, sPaP systolic pulmonary artery pressure,
PVR pulmonary vascular resistance, CI cardiac index, 6MWT 6 min walking test, IPAH idiopathic pulmonary arterial hypertension, APAH associated pulmonary
arterial hypertension
aWe have compared clinical features and hemodynamic parameters between patients with mutations in ENG gene and patients without mutations
bWe have compared clinical features and hemodynamic parameters between patients with p.G191N variation in ENG gene and patients without mutations
Fig. 2 Mutational frequency of each of the exons of the ENG gene. The pink color indicates the number of different mutations found in each
exon, and the purple color indicates the total of mutations found in each exon for the ENG gene
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and lower CI (p = 0.049). Finally, this change was more
prevalent in IPAH patients (p = 0.040). Other clinical and
hemodynamic parameters exhibited no statistically signifi-
cant differences. These results should be analyzed carefully
because all carriers for c.572G>A (p.G191D) variation but
one, were also carriers for mutations in others genes
(BMPR2, ACVRL1 and KCNA5).
Discussion
Mutations in the ENG gene have been described in up
to 88 % of HHT patients, including some with PAH
associated with HHT [29, 30]. In this study we have
identified a higher number of pathogenic mutations in
comparison with the results showed by other analysis
[4, 7, 17, 31–33]. All research conducted in ENG gene
have been performed in IPAH or HPAH patients, but
the study by Pfarr et al [7] described a small number of
pathogenic mutations in patients with congenital heart
disease associated to PAH. In 29 children with IPAH or
HPAH and 11 with APAH due to congenital heart disease
without any symptoms or familial history of HHT, Pfarr
et al [7] found 2 patients (5 %) carriers of mutations in the
Table 3 Missense changes found in the coding region of the ENG gene and their classification according to computer algorithms
(PolyPhen-2, Pmut, SIFT and MutationTaster2)
Classification of missense variations found in the coding region
Exon Nucleotide change Amino acid change Times detected PolyPhen-2 Pmut Sift Mutation Taster Score
Exon 5 c.572G>A p.(G191D) 10 Probably Damaging Pathological Damaging Disease causing 4
Exon 6 c.775G>A p.(V259M) 3 Probably Damaging Neutral Damaging Polymorphism 2
Exon 10 c.1295A>T p.(S432C) 2 Probably Damaging Pathological Tolerated Polymorphism 2
Exon 11 c.1402G>C p.(E468Q) 12 Probably Damaging Neutral Tolerated Polymorphism 1
Exon 11 c.1421T>A p.(F474Y) 6 Probably Damaging Neutral Tolerated Polymorphism 1
Exon 12 c.1633G>A p.(G545S) 1 Probably Damaging Pathological Tolerated Disease causing 3
Exon 12 c.1660C>A p.(R554C) 1 Probably Damaging Pathological Tolerated Polymorphism 2
These results are considered damaging if the score is equal or greater than two
Fig. 3 Representative sequence electropherograms for the missense variations for the ENG gene in PAH patients with their orthologs. 1: Homo
sapiens (sp|P17813#1); 2: Homo sapiens mutated (sp|P17813#1); 3: Mus musculus (sp|Q63961#1); 4: Rattus norvegicus (sp|Q6Q3E8#1); 5: Macaca
mulatta (sp|F7BB68#1); 6: Sus scrofa (sp|P37176#1); 7: Oryctolagus cuniculus (sp|G1SSF2#1); 8: Canis familiaris (sp|F1P847#1); 9: Bos taurus
(sp|Q1RMV1#1); 10: Equus caballus (sp|F6 W046#1); 11: Loxodonta africana (sp|G3SR82#1); 12: Ailuropoda melanoleuca (sp|G1 M9D6#1)
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ENG gene. However, in our cohort we included patients
with IPAH and associated with other pathologies. This
is the first mutational analysis of the ENG gene in
PAH patients associated to connective tissue disease,
human immunodeficiency virus and porto-pulmonary
hypertension.
We identified ENG mutations in 16 subjects, a signifi-
cantly higher percentage. We detected 5 ENG mutations
with potential pathogenicity not yet described and three
described sequence variants. Furthermore, with the in
silico analysis we were able to classify synonymous muta-
tions and mutations located in intronic junctions as patho-
genic mutations. However, other studies only focused on
the analysis of missense and nonsense mutations [7, 32].
Perhaps this fact can significantly increase the percentage
of pathogenic mutations in our patients. For these analyses
we used eight bioinformatic softwares that analyzed the
pathogenicity of the mutations. We considered PolyPhen,
Pmut, Sift and Mutation Taster softwares that analyze the
amino acid conservation, the protein function or the pro-
tein structure [21–24]. However, these softwares show
some differences in the criteria used to establish the
pathogenicity character of the variation. Some of them in-
cluded more information as the description of the variants
when is possible, the implication in the splicing process or
the presence of enhancer sequences. Besides, we used four
Table 4 Results from the four different bioinformatic programs used to predict the effect of missense, synonymous and intronic
changes on the splicing process in the ENG gene (NNSplice, NetGene2, Splice View and HSF Human)
Sequence variants Reference Genotype
frequency
NNSplice NetGene2 Splice View HSF Human Score
c.207G>A (p.(L69L)) rs11545664 G: 89 %
A: 11 %
Neutral Neutral Neutral A new acceptor site
is created
1
c.219+25G>T This study ———————— Neutral Neutral Neutral Neutral 0
c.360+56T>A This study ———————— Neutral Score for the main
donor site decreases
from 93 to 89
Neutral A new acceptor site
is created
2
c.498G>A (p.(Q166Q)) Pousada et al [8] G: 100 %
A: 0 %
Neutral Score for the main
donor site decreases
from 90 to 87
A new donor site
is created
Score for the main
acceptor site decrease
from 82 to 53
3
c.572G>A (p.(G191D)) Rs41322046
(Lesca et al [27])
G: 100 %
A: 0 %
Neutral Score for the main
acceptor site increase
from 18 to 19
Neutral Neutral 1
c.775G>A (p.(V259M)) This study ———————— Neutral Score for the main
acceptor site increase
from 35 to 37
Neutral A new acceptor site
is created
2
c.817+17T>A This study ———————— Neutral Score for the main
donor site decreases
from 100 to 99
Neutral Score for the main
acceptor site decrease
from 82 to 78
2
c.817+23G>A This study ———————— Neutral Neutral Neutral Neutral 0
c.991+21_991
+26dupCCTCCC
rs148063362 WT: 74 %
DUP: 26 %
Neutral Neutral Neutral Neutral 0
c.1272+6A>T This study ———————— Neutral Neutral A new donor site
is created
Score for the main
acceptor site decrease




This study ———————— Neutral Score for the main
donor site decreases
from 74 to 54
Neutral Score for the main
acceptor site decrease




rs370554511 G: 100 %
C: 0 %
Neutral Neutral The WT consensus
sequence is not
recognized
Score for the main
acceptor site increase




This study ———————— Neutral Neutral Neutral Score for the main
acceptor site decrease





(Pfarr et al [7])
G: 100 %
A: 0 %





COSM1105417 C: 100 %
A: 0 %
Neutral Score for the main
donor site decreases
from 69 to 67
Neutral A new acceptor site
is created
2
These results are considered positive if the score is equal or greater than two. The Genotype frequency values were for 1000 Genome Project. For novel
mutations, described in this study, no genotype data were available
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softwares that analyze the implication of the splicing
changes in the mRNA processing. In silico analysis is not
totally reliable, and for this reason we believe that analyze
this variants with several softwares is necessary to give us
a greater approach to catalogue a variant as polymorphism
or as pathogenic mutation. Functional studies would be
necessary to confirm the pathogenicity of these variants.
Aparisi et al [34] described that after exhaustive in silico
analysis with splicing softwares, only a few mutations
classified as pathogenic resulted really pathogenic in
Fig. 4 a Representative sequence electropherograms for the c.572G > A (p.(D191G)) mutation for the ENG gene in PAH patients. b Different
orthologs for this mutation. c Mutational frequency for this pathogenic mutation in IPAH and APAH patients. 1: Homo sapiens (sp|P17813#1);
2: Homo sapiens mutated (sp|P17813#1); 3: Mus musculus (sp|Q63961#1); 4: Rattus norvegicus (sp|Q6Q3E8#1); 5: Macaca mulatta (sp|F7BB68#1);
6: Sus scrofa (sp|P37176#1); 7: Oryctolagus cuniculus (sp|G1SSF2#1); 8: Canis familiaris (sp|F1P847#1); 9: Bos taurus (sp|Q1RMV1#1); 10: Equus caballus
(sp|F6W046#1); 11: Loxodonta africana (sp|G3SR82#1); 12: Ailuropoda melanoleuca (sp|G1M9D6#1)
Fig. 5 In vitro splicing assay for the c.572G > A (p.G191D) change identified in the ENG gene. a Electropherogram of the transcript obtained
indicates the molecular characterization of the effect of the studied variant. b Graphical representation of the effect of p.G191D change in mRNA
processing. c Electrophoresis of wild-type and mutant construction. SDS and SA2: pSPL3 vector exons, where the inserts to study are cloned
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the functional splicing analysis performed. In our study,
we have to take into account the fact that none of these
variations classified as pathogenic have been found in
healthy controls and the c.1633G>A (p.(G545S)) muta-
tion was been classified as pathogenic by other research
group [7].
We detected two hot spots for exons 6 and 12 in the
ENG gene. These exons are located in the extracellular
region (Zona pellucida-like domain) [7], a very import-
ant area rich in glycosylation sites and cysteine residues
[15, 20]. This region has a characteristic pattern of pre-
served residues [15, 20, 35]. Furthermore, Ali et al have
reported that missense mutations in this region for ENG
gene led to a decrease or disappearance of cell surface
expression of the protein [36]. Likewise, many missense
mutations located in an orphan domain, situated in a
Zona pellucida-like domain, resulted in protein misfold-
ing, altering the subcellular localization [35]. It is likely
that the mutated protein was retained by the endoplas-
mic reticulum (ER) quality control machinery [26, 36].
As a result, the protein becomes trapped in the rough
ER and is subjected to ER associated protein decay [26].
Thus, disruption of the downstream signaling of the
TGF-β pathway might be caused by mutations affecting
both the TGF-β/ALK1 and TGF-β/ALK5 balance and
the endothelial-cell growth potential [37–39]. The number
and class of molecules involved in this pathway, which dif-
fer among cells, underlie the great complexity and versatil-
ity of TGF-β signaling [31]. Moreover, in vitro studies on
pulmonary artery smooth muscle cells from IPAH patients
have indicated growth abnormalities [40].
Missense changes found in these patients are located
in aminoacidc residues highly conserved except p.(S432C)
and p.(R554C). These variations could be explained as
polymorphic change with evolutionary effects. Serine is a
non-essential polar amino acid that is neutrally charged,
and arginine is non-polar, essential and neutrally charged.
However, cysteine is non-essential and negatively charged.
The change in charge could be compensated with another
mutation in a region in close three-dimensional proximity.
Gallione et al [20] reported that cysteine amino acids are
involved in disulfide bridging. These mutations can pro-
duce alterations in the protein’s structure that affect its
functionality; the mutant allele could have a dominant
negative effect over the wild type allele, causing serious
consequences for carrier patients as have been described by
John et al [41] in the BMPR2 gene in patients with PAH.
The c.572G>A (p.(G191D) change has been previously
described as a polymorphism or rare variant [26–28]
despite being classified as pathogenic with four of the
computer programs used. For this reason and because
it is found at a very low frequency in the Spanish and
European control population, we performed functional
studies for this mutation to verify in vitro its pathogen-
icity. The analysis with the minigenes assay did not de-
tect any change in the splicing process. Förg T et al
[26] performed several colocalization experiments with
fluorescence microscopy, and the authors also classified
it as a polymorphism. Nonetheless, it is possible that
this change may act through other mechanisms, as the
complete role of ENG is still unknown and requires fur-
ther functional studies.
Furthermore, we found a pathogenic synonymous
change. Synonymous changes could interfere with the
splicing accuracy, translation fidelity, mRNA structure
and protein folding. Furthermore, these mutations may
decrease the half-life of mRNA, leading to downregulation
of the protein expression [8, 33]. Synonymous codons are
translated at lower levels than standard codons, since spe-
cific tRNA levels are decreased [42]. Functional studies for
synonymous mutations, intronic changes and intronic du-
plication would be very interesting, as the role of these
changes is unknown, and a functional approach could help
us to improve our knowledge of the disease.
Fig. 6 Mutational analysis of patients with multiple pathogenic mutations in analyzed genes
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In addition, we found that carriers of pathogenic mu-
tations were younger at diagnosis. This fact, together
with previous studies, indicates significant heterogen-
eity in the genetic background of PAH. Mutations in
the BMPR2 gene are most common in PAH patients,
but other genes may be related, including ACVRL1 or
KCNA5 [8]. All patients in this study were analyzed for
mutations in these three genes (BMPR2, ACVRL1 and
KCNA5) [8]. For the 57 patients analyzed for ENG
gene, 11 out of 16 patients exhibited only a mutation in
the ENG gene. Mutations in the ENG gene are quite
prevalent in our cohort of PAH patients, can influence
the development of the pathology and did not appear
in 55 control samples.
The ability of ENG to collaborate in the pathogenesis
is highly variable, as described by Mallet et al [43]. The
mutant protein could act in a haploinsufficient manner,
interacting with the wild type protein and interfering in
the normal endoglin function; alternatively, reduction or
loss of the cell surface expression of the mutant protein
has been described. As noted by John et al [41], we can-
not exclude other mechanisms, including the ability to
interact with other partners or to activate other signaling
pathways.
When we compared the hemodynamic and clinical pa-
rameters between patients with and without pathogenic
mutations, patients with mutations exhibited a signifi-
cantly earlier age at diagnosis (8 years compared with
patients without mutations) and a lower 6MWT. There-
fore, we cannot exclude the possibility that these differ-
ences may be due to the small number of patients in our
series. PAH exhibits highly variable clinical parameters,
and clinical diagnosis is complicated by the heterogeneous
outcome of disease manifestation; hence, additional
diagnostic tools are required to perform early diagnosis
in affected individuals.
Considering the patients with mutations only in the
ENG gene, we did not find significant differences in clin-
ical or hemodynamic parameters, but patients were diag-
nosed at an earlier age compare with patients without
mutations. Endoglin exhibits two different splice isoforms,
short (S) and long (L). Although the most common iso-
form of endoglin in endothelial cells is L-endoglin, Blanco
et al [44] reported that short S-endoglin expression con-
tributes to the cardiovascular pathology associated with
age in vivo and in vitro. These results suggest that S-
endoglin expression affects the senescent program of
endothelial cells when S-endoglin is upregulated instead
of being solely responsible for senescence. Furthermore,
Liu et al [45] reported that endoglin is also related to crit-
ical function in the development of the vascular system in
mouse embryonic stem cells, this could explain that
patients with pathogenic mutations have an early pres-
entation of the disease.
Previous studies in the BMPR2 gene indicate that PAH
patients carrying a mutation have an onset of disease ap-
proximately 10 years earlier than non-carriers [4] and
Liu et al [46] suggest that the phenotype of PAH patients
with BMPR2 mutations are influenced by gender. These
male patients have a more penetrant phenotype [46].
The former statement of the BMPR2 gene could be ex-
trapolated to the ENG gene, according to our results,
but we did not detect gender differences in this study.
As almost all of our patients with the c.572G>A
(p.G191D) change exhibited a pathogenic mutation in
other genes (BMPR2, ACVRL1 and KCNA5), we investi-
gated whether the presence of this change could modify
the phenotype. Pfarr et al [7] found significant differ-
ences for a low PVR value when they compared carriers
of mutations in the BMPR2, ACVRL1, ENG and SMAD
genes with non-pathogenic mutation carriers. Moreover,
we found significant differences in the age at diagnosis,
CI and PAH types when comparing hemodynamics and
clinical parameters between patients with the c.572G>A
(p.G191D) change vs patients without pathogenic muta-
tions in none analyzed genes. Patients harboring this
mutation exhibited significantly smaller CI values. We
found that this mutation was more prevalent in patients
with IPAH than in those APAH. Finally, this mutation
appears in patients who are diagnosed 10 years earlier
than non-carriers. As the specific mechanism for ENG is
not yet characterized and its relation with other PAH
genes remain unclear, these data should be cautiously
interpreted.
Five patients with pathogenic mutations in the ENG
gene also exhibited a mutation in another gene. Two of
these patients with p.(Q166Q) mutation in the ENG
gene [47] are carriers of p.(Q92L) and p.(V341M) BMPR2
gene mutations, classified as pathogenic [8]. Patient 3,
with a c.1272+6A > T mutation, was also a carrier of
the p.(W298*) mutation in the BMPR2 gene [8]. The
last two patients, with p.(G545S) [7] and c.817+17T>A
mutations, also harbored the p.(S232T) and p.(T243N)
ACVRL1 gene mutations, respectively. Mallet et al [43]
described several patients with pathogenic mutations in
different genes, including ENG, in HHT patients. The
authors proposed that one of the two mutations classi-
fied as pathogenic could be a rare variant [43], unlikely
to cause PAH. However, as observed in other human
pathologies, oligogenic inheritance of PAH with a major
causal gene should not be excluded [48]. Rodríguez-Viales
et al [49] proposed that additional variations can produce
a more severe phenotype and an early disease. The evalu-
ation of the total mutation load could be the way to
understand how mutations in different genes could be
responsible for the disease [50, 51]. This fact further
supports the importance of the functional analysis of
these mutants.
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The low number of patients included in this study repre-
sents a handicap to our ability to draw stronger conclu-
sions, but the comprehensive investigation and complete
follow-up of all cases adds value to our data. The high clin-
ical evaluation of these patients and the expertise in the
molecular methodology field make us confident about the
elevated presence of putative pathogenic mutations in these
patients. A functional study should be necessary in order to
corroborate the functional impact of these mutations.
Conclusion
To conclude, we described mutations in the ENG gene in
IPAH and APAH patients, some of which have not been
previously described. The vast majority of the mutations
found in this study are private, making difficult to establish
a correlation between the phenotype and a particular mu-
tation. For this reason, the genotype-phenotype correl-
ation was performed according to all mutations found in a
group of patients. Mutations in the ENG gene may influ-
ence the clinical status of the disease. Moreover, genetic
analysis in patients with PAH may be of clinical relevance
and demonstrates the complexity of the genetic back-
ground. A better understanding of the molecular basis will
support the future design of individualized treatments ac-
cording to the genetic background of each patient.
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